Apellis Pharma

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic and complement immunotherapies for the treatment of complement-dependent autoimmune and inflammatory diseases through APL-2 product. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Apellis Pharma reports strong Q1 revenue, eyes U.S. expansion

Apellis Pharma's Q1 2023 performance showcased strong revenue from SYFOVRE and EMPAVELI, with positive feedback and demand in the market.
While facing challenges like safety concerns and European commercialization, the company is focused on expanding market reach and driving awareness.
Opportunities lie in making SYFOVRE widely available, promoting patient education, and potential approval in Europe for further growth.

Apellis Pharma reports robust Q2 sales amidst safety event challenges

Apellis Pharma's Q2 performance highlighted strong sales, positive product efficacy, and proactive response to safety events
Despite challenges with rare safety events, the company's strengths in product credibility, manufacturing quality, and market acceptance shine through
Opportunities lie in enhancing physician education, exploring financing options, and leveraging positive efficacy evolution for market growth
Overall, Apellis Pharma's strategic measures position it well to navigate challenges, capitalize on opportunities, and maintain market confidence

Apellis Pharma reports mixed Q3 results, eyes European expansion

Apellis Pharma's Q3 performance showed strong revenue from key products but also highlighted the need for cost-saving measures. The company's focus on global expansion and product launches in Europe presents growth opportunities amidst market challenges.

Apellis Pharma reports strong Q4 earnings amidst market challenges

Apellis Pharma delivered strong financial results in Q4 2023, driven by the success of SYFOVRE and EMPAVELI in the U.S., while navigating challenges in the EU market and competitive landscape.
The company's strategic focus on patient access, market leadership, and R&D advancement positions it for continued growth and innovation in precision medicine, supported by robust engagement with medical communities.
Opportunities lie in expanding market share through bilateral treatments, advancing pipeline programs, and leveraging compliance and real-world data to strengthen Apellis Pharma's position as a leading provider of GA therapies.
Addressing challenges such as market competition, regulatory processes, and financial performance will be crucial for Apellis Pharma to sustain growth, optimize revenue, and drive profitability in the future.

Apellis Pharma reports robust Q1 performance and eyes expansion

Apellis Pharma (APLS) showcased strong financial performance and product success in Q1 2024, with plans for expansion and upcoming study data.
Despite challenges like a negative CHMP opinion and safety concerns, opportunities in education, expansion, and market penetration are on the horizon.
The company's commitment to shareholder value, financial stability, and milestone achievements sets a positive outlook for the future.

Apellis Pharma reports robust Q2 earnings, eyes market expansion

Apellis Pharma's Q2 performance reflects strong revenue growth and market leadership, supported by successful product sales and strategic initiatives.
While facing competition and challenges in market share retention, the company's focus on expansion and financial strength bode well for future growth.
Opportunities in new indications, market expansion, and pipeline development position Apellis Pharma for continued value creation for patients and shareholders.

Apellis Pharma reports robust Q3 performance amidst market challenges

Apellis Pharma's Q3 performance reflects strong demand for SYFOVRE and strategic initiatives to drive market share.
While facing challenges such as gross to net adjustments and market dynamics, the company remains optimistic about future growth opportunities.
By leveraging strengths in product efficacy and real-world data, Apellis Pharma aims to expand globally and enhance profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

CRESTWOOD, Ky., and WALTHAM, Mass., Sept.  11, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior notes due 2026 (the “notes”) in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Apellis also expects to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $30 million aggregate principal amount of the notes, solely to cover over-allotments, if any. The offering is subject to market and other conditions, and there can be no assurance as to whether, when or on what terms the offering may be completed.

Apellis Pharmaceuticals Announces Proposed Private Offering of $200 Million of Convertible Senior Notes

CRESTWOOD, Ky. and WALTHAM, Mass., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (NASDAQ: APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE is the second Phase 3 study that Apellis has initiated to investigate the potential of APL-2 to treat PNH. 

Apellis Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria

Dynavax Technologies

RedHill Biopharma

Here's what you need to know about the upgrades and bullish price targets analysts recently slapped on these drugmakers.

3 Biotech Stocks That Could Double Your Money.

News for Apellis Pharma Stock (APLS)